Abstract
Abstract 1216
Chronic myeloid leukemia (CML) begins as an indolent chronic-phase (CP) when a hematopoietic stem cell (HSC) expresses BCR-ABL, an oncogenic tyrosine kinase generated by the translocation t(9;22)(q34;q11) (i.e. Philadelphia chromosome, Ph). At this phase, BCR-ABL confers a proliferative/survival advantage to CD34+/CD38- primitive HSCs without affecting their multi-lineage capacity, as CD34+/CD38+ committed myeloid precursors (CMPs) are expanded but all BCR-ABL+ blood cells differentiate and function normally. Moreover, tyrosine kinase inhibitors of BCR-ABL (i.e., imatinib mesylate or dasatinib) induce durable remission in CML CP patients but do not eradicate leukemia-initiating cells, which therefore represent a reservoir of disease and potential source of relapse if therapy is stopped or discontinued. These findings strengthen the importance of unravelling HSC mechanisms that control early events on BCR-ABL+ leukemogenesis and therapy-responsiveness of primitive leukemic progenitors, being likely dictated not only by the BCR-ABL itself, but also by the specific HSC microenvironment that the oncogene targets. Here, we focus on glycogen synthase kinase-3β (GSK-3β), a nutrient-responsive kinase that is mainly regulated by serine (inhibitory) and tyrosine (stimulatory) phosphorylation in normal HSCs. It is known that GSK-3β plays multifaceted roles in haematopoiesis, by suppressing WNT/β-catenin pathway responsible for HSC maintenance on the one hand, or by promoting HSC survival and self-renewal through NF-kB activation on the other. Emerging evidence indicates GSK-3β targeting as an effective therapeutic approach in MLL leukemia, Alzheimer's disease and other neurodegenerative diseases, and administration of GSK3β inhibitors in vivo as a clinical means to augment the repopulating capacity of normal HSCs. We here describe balanced levels of transient inactive/active forms of GSK-3β phosphorylated at both serine9 (Ser9) and tyrosine216 (Y216) in normal CD34+ cells versus constitutive levels of active GSK-3β phospho-Y216 in total CD34+ cells and more primitive CD34+CD38- progenitors (<5% of total CD34+ cells) freshly-isolated from CML CP patients. Low or undetectable levels of GSK-3β phospho-Ser9 in primary BCR-ABL+ progenitors indicated that the kinase could be no longer regulated physiologically (e.g. defective inactivation). Imatinib 1mM, corresponding to plasma levels achieved in treated CML CP patients, effectively inhibited BCR-ABL kinase activity but enhanced GSK-3β phospho-Y216 without affecting total GSK-3β expression. Interestingly, increased GSK-3β phospho-Y216 correlated with up-regulated levels of active MAPK kinases in imatinib-treated CML progenitors, as part of a compensatory response induced by exogenous growth factor (GF)-stimulation for maintaining HSC viability. Indeed, imatinib did not change and, however, failed to increase GSK-3β phospho-Y216 in GF-starved CML CP progenitors. Immunofluorescence microscopy was then performed to test changes on the subcellular distribution of GSK-3β in response to BCR-ABL or cytokine stimulation. In normal CD34+ cells depleted of exogenous growth factors, GSK-3β was located predominantly in the cytoplasm, and 2h exposure to GF promoted its nuclear localization. In contrast, CML CD34+ cells showed a cytosolic retention of GSK-3β in presence of GF. By using imatinib (as a selective ABL inhibitor) and dasatinib (as a dual SRC/ABL inhibitor), we showed that CML progenitors can finely integrate oncogenic (BCR-ABL-dependent) and physiological survival signals (via GF-receptor engagement of SRC kinases), to control GSK-3β phospho-Y216, its subcellular distribution and signalling impact on downstream regulators of HSC maintenance (C/EBPα and p27), HSC viability (pp60SRC) and autophagy induction (mTOR). More importantly, our data point at therapeutic targeting of GSK-3β activity by SB-216763 combined with imatinib to strongly increase apoptosis in primary CML CD34+ cells resistant to the elimination by imatinib alone, while sparing normal HSCs. To sum up, this work gains new insights in the biology of primary BCR/ABL+ progenitors and earmarks GSK-3β as an attractive therapeutic target to overcome imatinib resistance in CML CP patients.
Disclosures:
No relevant conflicts of interest to declare.
Cytolethal distending toxin‐induced release of interleukin‐1β by human macrophages is dependent upon activation of glycogen synthase kinase 3β, spleen tyrosine kinase (Syk) and the noncanonical inflammasome